Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2014—PlatinumCode will donate five percent of its profits from the sale of pink products to breast cancer research. The company has launched various marketing efforts to help support breast cancer research, including providing clinical and hospital laboratories with its Pink Packs of samples.
November 2014—Leica Biosystems and Advanced Cell Diagnostics announced the comarketing of ACD’s RNAscope LS ISH assays using Leica’s Bond Rx research-use-only staining platform.
November 2014—Clinical laboratories running next-generation sequencing oncology tests now have access to a universal quality control material compatible with multiple sequencing platforms. The AcroMetrix Oncology Hotspot Control from Thermo Fisher Scientific provides a common quality control material that can be used in laboratories with different NGS instrument platforms, assays, and bioinformatics pipelines to test precision and detect analytical deviations that may arise from reagent and instrument variation.
November 2014—Agilent Technologies introduced ClearSeq AML, a next-generation cancer research panel that targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
November 2014—The Binding Site offers a line of anti-human blood protein antibodies for use by clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic manufacturers.
November 2014—Randox released a white paper focusing on the importance of quality control in point-of-care testing. The white paper will help laboratories define an appropriate QC procedure for all point-of-care devices.
November 2014—The ConfirmMDx for Prostate Cancer test, from MDxHealth, qualifies for Medicare coverage effective Nov. 3, 2014. The Centers for Medicare and Medicaid Services released the final version of the coverage policy issued by Palmetto GBA: MoIDX title: ConfirmMDx Epigenetic Molecular Assay, LCD No.: L35368.
November 2014—The Henry M. Jackson Foundation for the Advancement of Military Medicine has been awarded a patent in the U.S. and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada, and Japan.
November 2014—Biocartis announced the launch of its flagship molecular diagnostics system, Idylla. With Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test. Both Idylla and the Idylla BRAF Mutation Test have obtained CE-IVD marking.
